Search

Displaying results 4831 - 4840 of 10000 in total
  1. Drug

    OSU-6162

    go.drugbank.com/drugs/DB19178
    Investigational

    OSU-6162 is under investigation in clinical trial NCT05641623 (OSU6162 as Add-on in Ssri/snri-resistant Depression).

  2. Drug

    BCc1

    go.drugbank.com/drugs/DB16504
    Experimental

    BCc1 is a nanomedicine that demonstrated potent anticancer effects in both in vitro and in vivo studies.

  3. Drug

    Trenbolone

    go.drugbank.com/drugs/DB11551
    ExperimentalVet approved

    Plasma lipases then cleave the ester group in the bloodstream leaving free trenbolone. … Trenbolone, also known as trienolone or trienbolone, is a steroid used on livestock to increase muscle growth and appetite.

  4. Drug

    RTA 744

    go.drugbank.com/drugs/DB05920
    Investigational

    RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers. Anthracyclines are one of the most broadly used and effective cla...

  5. Drug

    Rilmenidine

    go.drugbank.com/drugs/DB11738
    ApprovedWithdrawn

    Rilmenidine has been used in trials studying the treatment of Hypertension and Chronic Kidney Disease.

  6. Drug

    Hypothiocyanite ion

    go.drugbank.com/drugs/DB15309
    Investigational

    Hypothiocyanite ion is under investigation in clinical trial NCT02598999 (Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients).

  7. Drug

    Trelagliptin

    go.drugbank.com/drugs/DB15323
    Investigational

    Trelagliptin is under investigation in clinical trial NCT03555591 (Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus").

  8. Drug

    LSZ-102

    go.drugbank.com/drugs/DB15362
    Investigational

    LSZ-102 is under investigation in clinical trial NCT02734615 (Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers).

  9. Drug

    CRx-139

    go.drugbank.com/drugs/DB05744
    Experimental

    CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. … It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects.

  10. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    The investigational drug was under investigation in clinical trial NCT00473928 (Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP)).